Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics.

Ekkelenkamp MB, Cantón R, Díez-Aguilar M, Tunney MM, Gilpin DF, Bernardini F, Dale GE, Elborn JS, Bayjanov JR, Fluit A

Antimicrobial agents and chemotherapy27 Jan 2020Cited by 34 (Europe PMC)

PMID31767727PMCIDPMC6985751DOI10.1128/aac.01541-19PepBankPUB-31767727

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Activity measurement
In cystic fibrosis respiratory isolates, murepavadin MIC50 was 0.12 mg/liter.
In plain wordsIn lab tests, murepavadin MIC50 was 0.12 mg/liter for cystic fibrosis bacterial isolates.
Peptide
Murepavadin
Outcome
Not applicableMIC50
Study
Pseudomonas aeruginosan = 414
Cystic fibrosis respiratory isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC50
0.12 mg/liter
Not specified
Source sentences
Summary
Murepavadin MIC₅₀ and MIC₉₀ were 0.12 mg/liter and 2 mg/liter, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen antibiotics and antibiotic combinations, including the novel antibacterial peptide murepavadin, were tested for activity against 414 Pseudomonas aeruginosa isolates cultured from respiratory samples of CF patients.
Report a problemFND-3176772701
02LabIn vitro (cells)Activity measurement
In cystic fibrosis respiratory isolates, murepavadin MIC90 was 2 mg/liter.
In plain wordsIn lab tests, murepavadin MIC90 was 2 mg/liter for cystic fibrosis bacterial isolates.
Peptide
Murepavadin
Outcome
Not applicableMIC90
Study
Pseudomonas aeruginosan = 414
Cystic fibrosis respiratory isolates
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
Dose not stated
Measurements
MIC90
2 mg/liter
Not specified
Source sentences
Summary
Murepavadin MIC₅₀ and MIC₉₀ were 0.12 mg/liter and 2 mg/liter, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen antibiotics and antibiotic combinations, including the novel antibacterial peptide murepavadin, were tested for activity against 414 Pseudomonas aeruginosa isolates cultured from respiratory samples of CF patients.
Report a problemFND-3176772702

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.